Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

Table 1

Characteristics of trials about the first-line therapy.

Studies	Intervention	Patients	Median follow-up (mo)	Median OS and 95% CI (mo)	HR and 95% CI for OS	Median PFS and 95% CI (mo)	HR and 95% CI for PFS	Jadad score
Hurwitz et al. 2004 (AVF2107) [3]	IFL + B	402	Not reported	20.3	0.69 [0.59, 0.81]	10.6	0.66 [0.58, 0.76]	4
	IFL	411		15.6^∧		6.2^∧
Kabbinavar et al. 2003 [12]	Fu + LV + Bh	33	Not reported	16.1 [11.0–20.7]	Not reported	7.2 [3.8–9.2]	0.54 [0.33, 0.88]	3
	Fu + LV + Bl	35		21.5 [17.3-undetermined]		9.0 [5.8–10.9]
	Fu + LV	36		13.8 [9.1–23.0]		5.2 [3.5–5.6]
Kabbinavar et al. 2005 [13]	Fu + LV + B	104	Not reported	16.6	0.79 [0.56, 1.10]	9.2	0.50 [0.34, 0.73]	4
	Fu + LV	105		12.9^∧		5.5^∧
Saltz et al. 2008 (N016966)* [14]	XELOX + B	350	27.6	Not reported	0.84 [0.71, 1.01]	Not reported	0.77 [0.65, 0.92]	4
	XELOX	350		Not reported		Not reported
	FOLFOX-4 + B	350	27.6	Not reported	0.94 [0.77, 1.15]	Not reported	0.89 [0.74, 1.06]	4
	FOLFOX-4	351		Not reported		Not reported
ITACA* [11]	FOLFOX-4 or FOLFIRI + B	179	Unclear^#	20.6 [15.3, 22.6]	1.18 [0.88, 1.58]	9.2 [8.0, 10.0]	0.88 [0.70, 1.10]	≥3
	FOLFOX-4 or FOLFIRI	197		20.6 [18.2, 23.3]		8.4 [7.0, 8.9]
Stathopoulos et al. 2010 [15]	mIFLl + B	114	72	22.0 [18.1, 25.9]	1.05 [0.81, 1.36]	Not reported	Not reported	3
	mIFL	108		25.0 [18.1–31.9]		Not reported
Tebbutt et al. 2010 (MAX) 2 [16]	CBM	158	21.5	16.4	0.94 [0.73, 1.21]	8.4 [7.5–9.0]	0.59 [0.47, 0.75]	3
	C	156		18.9^∧		5.7 [5.4–6.2]
Tebbutt et al. 2010 (MAX) 1 [16]	CB	157	48	Not reported	0.88 [0.68, 1.13]	8.5 [7.3–9.2]	0.63 [0.50, 0.79]	3
	C	156		Not reported		5.7 [5.4–6.2]

∗The most used combination chemotherapy in metastatic colorectal cancer. ^#The data is unclear because it is just extracted from the abstract from 2013 ASCO annual meeting. ^∧95% CI was not reported.
B: bevacizumab, Bl: bevacizumab in low doses, Bh: bevacizumab in high doses, XELOX: Xeloda plus oxaliplatin regimen, FOLFOX: 5-Fu, LV, and oxaliplatin regimen.
FOLFIRI: 5-Fu, LV, and irinotecan regimen, mIFL: modified irinotecan, LV, and 5-Fu regimen, CBM: capecitabine, bevacizumab, and mitomycin regimen.
CB: capecitabine and bevacizumab regimen, C: capecitabine.